Axonal injury in multiple sclerosis

Handbook of Multiple Sclerosis, Third Edition

Volumn , Issue , 2001, Pages 325-345

  Bjartmar, Carl ^a   Trapp, Bruce D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009664792     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (123)

1. Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion. Brain 1991; 114:1271-1280.
2. Arnold DL, Reiss GT, Matthews PM, Francis GS, Collins DL, Wolfson C, Antel JP. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36:76-82.
3. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, McDonald WI, Miller DH. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118:1583-1592.
4. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120:393-399.
5. Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, Antel JP, Matthews PM, Arnold DL. Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997; 41:385-391.
6. Lassmann H. Neuropathology in multiple sclerosis: New concepts. Mult Scler 1998; 4:93-98.
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-285.
8. van Waesberghe JHTM, Kamphorst W, De Groot CJA, van Walderveen MAA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46:747-754.
9. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: Relationship to neurological disability. Neuroscientist 1999; 5:48-57.
10. Kornek B, Lassman H. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 1999; 9:651-656.
11. Charcot, M. Histologie de le sclerose en plaques. Gazette Hopitaux 1868; 141:554-558.
12. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
13. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38:901-909.
14. Losseff NA, Webb SL, O’Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ. Spinal cord atrophy and disability in multiple sclerosis: A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119:701-708.
15. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ. Progressive cerebral atrophy in multiple sclerosis: A serial MRI study. Brain 1996; 119:2009-2019.
16. Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, Francis G, Antel J, Wolfson C, Arnold DL. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119:715-722.
17. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121:103-113.
18. van Walderveen MAA, Kamphorst W, Scheltens P, van Waesberghe JHTM, Ravid R, Valk J, Polman CH, Barkhof F. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50:1282-1288.
19. Brown A, McFarlin DE, Raine CS. Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab Invest 1982; 46:171-185.
20. Raine CS, Cross AH. Axonal dystrophy as a consequence of long-term demyelination. Lab Invest 1989; 60:714-725.
21. Njenga MK, Murray PD, McGavern D, Lin X, Drescher KM, Rodriguez M. Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler’s virus. J Neuropathol Exp Neurol 1999; 58:78-91.
22. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469-1477.
23. Losseff NA, Miller DH. Measures of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64:S102-S105.
24. Bjartmar C, Yin X, Trapp BD. Axonal pathology in myelin disorders. J Neurocytol 1999; 28:383-395.
25. Waxman SG. Demyelinating diseases-New pathological insights, new therapeutic targets. N Engl J Med 1998; 338:223-225.
26. Bostock H, Sears TA, The internodal axon membrane: Electrical excitability and continuous conduction in segmental demyelination. J Physiol (Lond) 1978; 280:273-301.
27. Foster RE, Whalen CC, Waxman SG. Reorganization of the axon membrane in demyelinated peripheral nerve fibers: Morphological evidence. Science 1980; 210:661-663.
28. Felts PA, Baker TA, Smith KJ. Conduction in segmentally demyelinated mammalian central axons. J Neurosci 1997; 17:7267-7277.
29. Marburg O. Die sogenannte '‘akute multiple Sklerose’’ (Encephalomyelitis peraxialis scleroticans). Jahrb Neurol Psychiatry 1906; 27:211-312.
30. Putnam TJ. Studies in multiple sclerosis. Arch Neurol Psychiatry 1936; 35:1289-1308.
31. Greenfield JG, King LS. Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain 1936; 59:445-458.
32. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Nat Acad Sci USA 1990; 87:1561-1565.
33. Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD. Axonal loss correlates with reduced N-acetyl-aspartate levels in chronic multiple sclerosis lesions of the spinal cord (abstr). J Neurochem 2000; 74:S13. (Suppl for American Society for Neurochemistry.)
34. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1962; 25:315-320.
35. Lumsden CE. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology, vol 9. Amsterdam: North-Holland, 1970, pp 217-309.
36. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999; 122:17-26.
37. Peterson JW, Bö L, Chang A, Mörk S, Trapp BD. Neuropathology of cortical lesions in multiple sclerosis (abstr). J Neurochem 2000; 74:S13. (Suppl for American Society for Neurochemistry.)
38. Damian MS, Schilling G, Bachmann G, Simon C, Stoppler S, Dorndorf W. White matter lesions and cognitive deficits: Relevance of lesion pattern? Acta Neurol Scand 1994; 90: 430-436.
39. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology 1991; 41:685-691.
40. Ron MA, Callanan MM, Warrington EK. Cognitive abnormalities in multiple sclerosis: A psychometric and MRI study. Psychol Med 1991; 21:59-68.
41. Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology 1995; 45:718-723.
42. Foong J, Rozewics L, Davie CA, Thompson AJ, Miller DH, Ron MA. Correlates of executive function in multiple sclerosis: The use of magnetic resonance spectroscopy as an index of focal pathology. J Neuropsychiatr Clin Neurosci 1999; 11:45-50.
43. Stevenson VL, Miller DH. Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Mult Scler 1999; 5:268-272.
44. Isaac C, Li DK, Genton M, Jardine C, Grochowski E, Palmer M, Kastrukoff LF, Oger J, Paty DW. Multiple sclerosis: A serial study using MRI in relapsing patients. Neurology 1988; 38:1511-1515.
45. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53:1698-1704.
46. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978; 4:151-162.
47. Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Mosley IF, MacManus DG, McDonald WI, Miller DH. Spinal cord MRI using multi-array coils and fast spin echo: II. Findings in multiple sclerosis. Neurology 1993; 43:2632-2637.
48. Filippi M, Colombo B, Rovaris M, Pereira C, Martinelli V, Comi G. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. J Neuroimaging 1997; 7: 78-80.
49. Simon JH, Jacobs LD, Campion MK, Rudick MA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fisher JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE, Brownscheidle CM, The Multiple Sclerosis Collaborative Research Group (MSCRG). A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999; 53:139-148.
50. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassman H. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42:783-793.
51. Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, Arnold DL. Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis. Semin Neurol 1998; 18:327-336.
52. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989; 13:23-31.
53. Moffett JR, Namboodiri MAA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991; 2:131-134.
54. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45:37-45.
55. Graham GD, Blamire AM, Howseman AM, Rothman DL, Fayad PB, Brass LM, Petroff OA, Shulman RG, Prichard JW. Proton magnetic resonance spectroscopy of cerebral lactate and other metabolites in stroke patients. Stroke 1992; 23:333-340.
56. Pioro E, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994; 44:1933-1938.
57. Narayana PA, Doyle TJ, Dejian L, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43:56-71.
58. Clarke DD, Greenfield S, Dicker E, Tirri LJ, Ronan EJ. A relationship of N-acetylaspartate biosynthesis to neuronal protein synthesis. J Neurochem 1975; 24:479-485.
59. Cangro CB, Namboodiri MA, Sklar LA, Corigliano-Murphy A, Neale JH. Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. J Neurochem 1987; 49:1579-1588.
60. Lee JH, Arcinue E, Ross BD. Brief report: Organic osmolytes in the brain of an infant with hypernatremia. N Engl J Med 1994; 331:439-442.
61. Patel TB, Clark JB. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and involvement in mitochondrial/cytosolic carbon transport. Biochem J 1979; 184:539-546.
62. Truckenmiller ME, Namboodiri MAA, Brownstein MJ, Neale JH. N-acetylation of L-aspartate in the nervous system: Differential distribution of a specific enzyme. J Neurochem 1985; 45:1658-1662.
63. Sager TN, Thomsen C, Valsborg JS, Laursen H, Hansen AJ. Astroglia contain a specific transport mechanism for N-acetyl-L-aspartate. J Neurochem 1999; 73:807-811.
64. Rosenbluth J. Role of glial cells in the differentiation and function of myelinated axons. Int J Dev Neurosci 1988; 6:3-24.
65. Dugandzija-Novakovic S, Koszowski AG, Levinson SR, Shrager P. Clustering of Na+ channels and node of Ranvier formation in remyelinating axons. J Neurosci 1995; 15:492-503.
66. Kaplan MR, Meyer-Franke A, Lambert S, Bennett V, Duncan ID, Levison SR, Barres BA. Induction of sodium channel clustering by oligodendrocytes. Nature 1997; 386:724-728.
67. de Waegh SM, Lee VM-Y, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 1992; 68:451-463.
68. Windenbank AJ, Wood P, Bunge RP, Dyck PJ. Myelination determines the caliber of dorsal root ganglion neurons in culture. J Neurosci 1985; 5:1563-1569.
69. Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 1996; 16:5095-5105.
70. Rango M, Spagnoli D, Tomei G, Bamonti F, Scarlato G, Zetta L. Central nervous system trans-synaptic effects of acute axonal injury: A 1H magnetic resonance spectroscopy study. Magn Reson Med 1995; 33:595-600.
71. Hafer-Macko C, Hsieh S-T, Li CY, Ho TW, Sheikh K, Cornblath DR, McKhann GM, Asbury AK, Griffin JW. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol 1996; 40:635-644.
72. Ho TW, McKhann GM, Griffin JW. Human autoimmune neuropathies. Ann Rev Neurosci 1998; 21:187-226.
73. Rudick RA, Goodman A, Herndon RM, Panitch HS. Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment. J Neuroimmunol 1999; 98:22-28.
74. Simon JH, Jacobs LD, Campion M. Magnetic resonance studies of intramuscular interferon ß-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43:79-87.
75. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997; 120:865-916.
76. Powell HC, Myers RR. The axon in Guillain-Barré syndrome: Immune target or innocent bystander? Ann Neurol 1996; 39:4-5.
77. Giese KP, Martini R, Lemke G, Soriano P, Schachner M. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 1992; 71:565-576.
78. Anzini P, Neuberg DH, Schachner M, Nelles E, Willecke K, Zielasek J, Toyka KV, Suter U, Martini R. Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci 1997; 17:4545-4551.
79. Yin X, Crawford TO, Griffin JW, Tu P, Lee VM-Y, Li C, Roder J, Trapp BD. Myelinassociated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 1998; 18:1953-1962.
80. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, Schneider A, Zimmermann F, McCulloch M, Nadon N, Nave K-A. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998; 280:1610-1613.
81. Sahenk Z, Chen L, Mendell JR. Effects of PMP22 duplication and deletions on the axonal cytoskeleton. Ann Neurol 1999; 45:16-24.
82. Sheikh KA, Sun J, Liu Y, Kawai H, Crawford TO, Proia RL, Griffin JW, Schnaar RL. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Nat Acad Sci USA 1999; 96:7532-7537.
83. Salzer JL, Holmes WP, Colman DR. The amino acid sequences of the myelin-associated glycoproteins: Homology to the immunoglobulin gene superfamily. J Cell Biol 1987; 104: 957-965.
84. Arquint M, Roder J, Chia L-S, Down J, Wilkinson O, Bayley H, Braun P, Dunn R. Molecular cloning and primary structure of myelin-associated glycoproteins. Proc Nat Acad Sci USA 1987; 84:600-604.
85. Lai C, Brow MA, Nave K-A, Noronha AB, Quarles RH, Bloom FE, Milner RJ, Sutcliffe JG. Two forms of 1B236/myelin-associated glycoprotein (MAG), a cell adhesion molecule for postnatal neural development, are produced by alternative splicing. Proc Nat Acad Sci USA 1987; 84:4337-4341.
86. Sternberger NH, Quarles RH, Itoyama Y, Webster HD. Myelin-associated glycoprotein demonstrated immunocytochemically in myelin and myelin forming cells of developing rats. Proc Nat Acad Sci USA 1979; 76:1510-1514.
87. Trapp BD, Andrews SB, Cootauco C, Quarles RH. The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J Cell Biol 1989; 109:2417-2426.
88. McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE. Identification of myelinassociated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 1994; 13:805-811.
89. Mukhopadhya G, Doherty P, Walsh FS, Crocker P, Filbin MT. A novel role for myelinassociated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994; 13:757-767.
90. Li M, Shibata A, Li C, Braun PE, McKerracher L, Roder J, Kater SB, David S. Myelinassociated glycoprotein inhibits neurite/axon growth and causes growth cone collapse. J Neurosci Res 1996; 46:404-414.
91. Duncan ID, Hammang JP, Trapp BD. Abnormal compact myelin in the myelin-deficient rat: Absence of proteolipid protein correlates with a defect in the intraperiod line. Proc Nat Acad Sci USA 1988; 84:6287-6291.
92. Hodes ME, Pratt VM, Dlouhy SR. Genetics of Pelizaeus-Merzbacher disease. Dev Neurosci 1993; 15:383-394.
93. Seitelberger F. Neuropathology and genetics of Pelizaeus-Merzbacher disease. Brain Pathol 1995; 5:267-273.
94. Inoue K, Osaka H, Imaizumi K, Nezu A, Takanashi J, Arii J, Murayama K, Ono J, Kikawa Y, Mito T, Shaffer LG, Lupski JR. Proteolipid protein gene duplications causing Pelizaeus-Merzbacher disease: Molecular mechanism and phenotypic manifestations. Ann Neurol 1999; 45:624-632.
95. Griffiths IR, Schneider A, Anderson J, Nave K-A. Transgenic and natural mouse models of proteolipid protein (PLP) related dysmyelination and demyelination. Brain Pathol 1995; 5: 275-281.
96. Anderson TJ, Schneider A, Barrie JA, Klugmann M, McCulloch MC, Kirkham D, Kyriakides E, Nave K-A, Griffiths IR. Late-onset neurodegeneration in mice with increased dosage of the proteolipid protein gene. J Comp Neurol 1998; 394:506-519.
97. Hanemann CO, Müller HW. Pathogenesis of Charcot-Marie-Tooth IA (CMTIA) neuropathy. Trends Neurosci 1998; 21:282-286.
98. Hayasaka K, Himoro M, Sato W, Takada G, Uyemura K, Shimizu N, Bird TD, Coneally PM, Chance PF. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nature Genet 1993; 5:31-34.
99. Bergoffen J, Scherer SS, Wang S, Oronzi Scott M, Bone LJ, Paul DL, Chen K, Lensch MW, Chance PF, Fischbeck KH. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993; 262:2039-2042.
100. Dyck PJ, Karnes JL, Lambert EH. Longitudinal study of neuropathic deficits and nerve conduction abnormalities in hereditary motor and sensory neuropathy type 1. Neurology 1989; 39:1302-1308.
101. Scherer SS, Xu YT, Nelles E, Fischbeck K, Bone LJ. Connexin32-null mice develop demyelinating peripheral neuropathy. Glia 1998; 24:8-20.
102. Scherer S. Axonal pathology in demyelinating diseases. Ann Neurol 1999; 45:6-7.
103. Low PA, McLeod JG. Hereditary demyelination neuropathy in the Trembler mouse. J Neurol Sci 1975; 26:565-574.
104. Aguayo A, Attiwell M, Trecarten J, Perkins S, Bray G. Abnormal myelination in transplanted Trembler mouse Schwann cells. Nature 1977; 265:73-75.
105. Sahenk Z, Chen L. Abnormalities in the axonal cytoskeleton induced by a Connexin32 mutation in nerve xenografts. J Neurosci Res 1998; 51:174-184.
106. Raine CS. Biology of disease. Analysis of autoimmune demyelination: Its impact upon multiple sclerosis. Lab Invest 1984; 50:608-635.
107. Owens T, Sriram S. The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Neurol Clin 1995; 13:51-73.
108. Linington C. Experimental animal models. In: Zhang J, Hafler D, Hohlfeld R, Miller A, eds. Immunotherapy in Neuroimmunologic Diseases. London: Martin Dunitz, 1998, pp 11-28.
109. Yu M, Nishiyama A, Trapp BD, Tuohy V. Interferon-ß inhibits progression of relapsingremitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996; 64:91-100.
110. Wujek JR, Bjartmar C, Richer E, Yu M, Tuohy V, Trapp BD. Loss of spinal cord axons in the experimental allergic encephalomyelitis animal model of multiple sclerosis (abstr). J Neurochem 2000; 74:S46. (Suppl for American Society for Neurochemistry; 74:546).
111. Bell JI, Lathrop GM. Multiple loci for multiple sclerosis. Nature Genet 1996; 13:377-378.
112. Ebers GC, Dyment DA. Genetics of multiple sclerosis. Semin Neurol 1998; 18:295-299.
113. Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999; 399(suppl):A40-A47.
114. Rodriguez M, Oleszak E, Leibowitz J. Theiler’s murine encephalomyelitis: A model of demyelination and persistence of virus. Crit Rev Immunol 1987; 7:325-365.
115. Drescher KM, Pease LR, Rodriques M. Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis. Immunol Rev 1997; 159:177-193.
116. Rivera-Quinones C, McGavern D, Schmelzer JD, Hunter SF, Low PA, Rodriguez M. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nature Med 1998; 4:187-193.
117. Lloyd KG. CNS compensation to dopamine neuron loss in Parkinson’s disease. Adv Exp Med Biol 1977; 90:255-266.
118. Bradley WG. Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies. Muscle Nerve 1987; 10:490-502.
119. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32:758-766.
120. Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995; 45:255-260.
121. Mews I, Bergmann M, Bunkowski S, Gullotta F, Brück W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998; 4:55-62.
122. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996; 46:907-911.
123. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997; 337:1604-1611.